PT-141 (Bremelanotide, FDA-approved as Vyleesi for HSDD) is the well-characterized entry. Different mechanism than PDE5 inhibitors — it acts on desire, not blood flow.
1 entries in Libido
PT-141 (Bremelanotide, FDA-approved as Vyleesi for HSDD) is the well-characterized entry. Different mechanism than PDE5 inhibitors — it acts on desire, not blood flow.